Bristol-myers Squibb Compnay

Syngene International Limited

Lawrence J Kennedy

Jun Li

Yan Shi

Peter Tai Wah Cheng

James R Corte

Hao Zhang

Jun Shi

Shiwei Tao

Robert F Kaltenbach, Iii

Ying Wang

Tianan Fang

Steven J Walker

Jeffrey A Robl

Sutjano Jusuf

Kumaravel Selvakumar

Haixia Wang

Suresh Dhanusu

Ramesh Babu Reddigunta

James J Li

Chenkou Wei

Michael A Galella

Jie Jack Li

Peter Tai Cheng

Lawrence G Hamann

Saleem Ahmad

William N Washburn

Khehyong Ngu

Xinhua Qian

Stephen P O'Connor

Robert F Kaltenbach

Rajendra P Deshpande

Reginald O Cann

Laxma Reddy Kolla

Robert F Kaltenbach Iii

Ramesh Badu Reddigunta

Iii Robert F Kaltenbach

Robert F Iii Kaltenbach

Stephen P O'CONNOR

The present invention provides compounds of Formula (I): or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.

Triazole n-linked carbamoyl cyclohexyl acids as LPA antagonists

Triazole N-linked carbamoyl cyclohexyl acids as LPA antagonists

The present invention provides compounds of Formula (I): or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.

Carbamoyloxymethyl triazole cyclohexyl acids as LPA antagonists

The present invention provides compounds of Formula (I): Formula (I) or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors. 

Cyclohexyl acid triazole azoles as LPA antagonists

Cyclohexyl acid triazole azines as LPA antagonists

The present invention provides compounds of Formula (I) or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors. 

Pyrazole O-linked carbamoyl cyclohexyl acids as LPA antagonists

Novel compounds of Formula I:or an enantiomer, diastereomer, tautomer, prodrug or salt thereof, wherein m, Q, T, U, V, ring A, X, Y, R, R, R, R, R, R, R, R, R, R, and Rare defined herein, are provided which are TGR5 G protein-coupled receptor modulators. TGR5 G protein-coupled receptor modulators are useful in treating, preventing, or slowing the progression of diseases requiring TGR5 G protein-coupled receptor modulator therapy. Thus, the disclosure also concerns compositions comprising these novel compounds and methods of treating diseases or conditions related to the activity of the TGR5 G protein-coupled receptor by using any of these novel compounds or a composition comprising any of such novel compounds. 

Bicyclic nitrogen containing heteroaryl TGR5 receptor modulators

Novel compounds are provided which are 1 1-beta-hydroxysteroid dehydrogenase type I inhibitors. 1 1-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 1 1-beta-hydroxysteroid dehydrogenase type I inhibitor therapy. These novel compounds have the structure: W-L-Z or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein W, L are defined herein and Z is selected from the following bicyclic heteroaryl groups: (a), (b), (c), (d). 

Substituted [1,2,4]triazolo[4,3-A]pyrazine 11-beta-hydroxysteroid dehydrogenase inhibitors

Novel compounds are provided which are 11-beta-hydroxysteroid dehydrogenase type I inhibitors. 11-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11-beta-hydroxysteroid dehydrogenase type I inhibitor therapy. These novel compounds of formula I: or stereoisomers or pharmaceutically acceptable salts thereof, wherein G, Q, X, Y, R, R, and Rare defined herein.

Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors

Growing community of inventors

Titusville, NJ, United States of America

Lawrence J Kennedy